Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

730 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators. Cohen EEW, et al. Among authors: ahn mj. Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30. Lancet. 2019. PMID: 30509740 Clinical Trial.
Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer.
Chang MH, Kim KH, Jun HJ, Kim HS, Yi SY, Uhm JE, Park MJ, Lim DH, Ji SH, Hwang IG, Lee J, Park YH, Ahn JS, Ahn MJ, Park K. Chang MH, et al. Among authors: ahn js, ahn mj. Cancer Chemother Pharmacol. 2009 Oct;64(5):917-24. doi: 10.1007/s00280-009-0943-7. Epub 2009 Feb 17. Cancer Chemother Pharmacol. 2009. PMID: 19221753 Clinical Trial.
Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
Sun JM, Lee KH, Kim SW, Lee DH, Min YJ, Yun HJ, Kim HK, Song HS, Kim YH, Kim BS, Hwang IG, Lee K, Jo SJ, Lee JW, Ahn JS, Park K, Ahn MJ; Korean Cancer Study Group. Sun JM, et al. Among authors: ahn js, ahn mj. Cancer. 2012 Dec 15;118(24):6234-42. doi: 10.1002/cncr.27630. Epub 2012 Jun 6. Cancer. 2012. PMID: 22674612 Free article. Clinical Trial.
A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01).
Ji JH; Korean Cancer Study Group (KCSG); Yun T, Kim SB, Kang JH, Park JC, Cho IS, Sohn CH, Heo DS, Jang JS, Shin SW, Hwang DW, Sun JM, Park K, Ahn MJ. Ji JH, et al. Among authors: ahn mj. Eur J Cancer. 2012 Nov;48(17):3198-204. doi: 10.1016/j.ejca.2012.06.009. Epub 2012 Jul 13. Eur J Cancer. 2012. PMID: 22795584 Clinical Trial.
Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
Kim HS, Kwon HJ, Jung I, Yun MR, Ahn MJ, Kang BW, Sun JM, Kim SB, Yoon DH, Park KU, Lee SH, Koh YW, Kim SH, Choi EC, Koo DH, Sohn JH, Kim B, Kwon NJ, Yun HJ, Lee MG, Lee JH, Kim TM, Kim HR, Kim JH, Paik S, Cho BC. Kim HS, et al. Among authors: ahn mj. Clin Cancer Res. 2015 Feb 1;21(3):544-52. doi: 10.1158/1078-0432.CCR-14-1756. Epub 2014 Nov 25. Clin Cancer Res. 2015. PMID: 25424851 Clinical Trial.
Pembrolizumab for the treatment of non-small-cell lung cancer.
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L; KEYNOTE-001 Investigators. Garon EB, et al. Among authors: ahn mj. N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19. N Engl J Med. 2015. PMID: 25891174 Free article. Clinical Trial.
730 results